Plasma levels of dopamine metabolite correlate with mismatch negativity in patients with schizophrenia.
Psychiatry Clin Neurosci
; 74(5): 289-293, 2020 May.
Article
em En
| MEDLINE
| ID: mdl-31994282
ABSTRACT
AIM:
Mismatch negativity (MMN) deficit is one of the most robust and replicable findings in schizophrenia, and primarily reflects deficient functioning of the N-methyl-D-aspartate (NMDA) receptor system. Although the dopamine receptor is known not to modulate MMN over the short term, it is unclear whether the dopamine system affects MMN in the long term.METHODS:
We explored correlations between MMN and levels of plasma dopamine and serotonin metabolites in 18 patients with schizophrenia psychiatrically evaluated with the Positive and Negative Syndrome Scale (PANSS).RESULTS:
A significant negative correlation exists between MMN amplitude and plasma levels of dopamine metabolites. Plasma serotonin metabolite levels were not correlated with MMN. The PANSS total score and Negative score also showed negative correlations with MMN amplitude.CONCLUSION:
The usual strong therapeutic blockade of dopamine receptors applied in cases of schizophrenia may reduce MMN over the long term.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esquizofrenia
/
Dopamina
/
Potenciais Evocados
/
Ácido Homovanílico
/
Ácido Hidroxi-Indolacético
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Psychiatry Clin Neurosci
Assunto da revista:
NEUROLOGIA
/
PSIQUIATRIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Japão